Besides, biomarkers including PD-L1 expression, PD-L2 expression, and other gene signatures showed a potential effect of HNSCC which developed the novel target treatment in patients with HNSCC (Solomon et al. 2018; Leemans et al. 2018; Farmer et al. 2019). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.